Nephrol Dial Transplant. 1988;3(6):714-27.
The demography of renal replacement therapy for 1985 and 1986 is presented, based on returns of individual patient questionnaires to the EDTA Registry, supplemented by some data from the centre questionnaire. Patient questionnaires for 1985 were received from 83% of known centres and for 1986 from 79% of known centres in 33 countries. Of 244,497 individually registered patients, 116,892 were known to be alive on defined forms of renal replacement therapy on 31 December 1985 and 121,755 on 31 December 1986. Countries covered by the EDTA Registry include one-third of the world's population on renal replacement therapy. Individual countries exemplify different strategies with variable proportional contributions from home haemodialysis, CAPD and transplantation, and varying levels of achievement in numbers of patients on treatment. Trends in patient populations demonstrate that standard risk patients (aged under 55 and non-diabetic) are mostly receiving treatment in countries with advanced programmes, whereas the growth in numbers of new patients is due largely to increase in the acceptance of high-risk patients (aged over 55 or with diabetes mellitus). These trends have implications for the future; predictions must take account of the variable mixture of standard and high-risk patients, the different results achieved in these categories and the rates at which the mixture between them is changing.
本文呈现了1985年和1986年肾脏替代治疗的人口统计学数据,这些数据基于各个患者对欧洲透析与移植协会(EDTA)登记处问卷的回复,并辅以来自中心问卷的一些数据。1985年的患者问卷来自33个国家中83%的已知中心,1986年的来自79%的已知中心。在244,497名单独登记的患者中,已知在1985年12月31日有116,892人接受特定形式的肾脏替代治疗且存活,在1986年12月31日有121,755人存活。EDTA登记处覆盖的国家包括世界上三分之一接受肾脏替代治疗的人口。各个国家体现了不同的策略,家庭血液透析、持续性不卧床腹膜透析(CAPD)和移植的贡献比例各不相同,治疗患者数量的成就水平也各异。患者群体的趋势表明,标准风险患者(年龄在55岁以下且非糖尿病患者)大多在项目先进的国家接受治疗,而新患者数量的增长主要归因于高风险患者(年龄超过55岁或患有糖尿病)接受度的提高。这些趋势对未来有影响;预测必须考虑标准风险患者和高风险患者的不同组合、这些类别中取得的不同结果以及它们之间组合的变化速率。